Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Total Liabilities (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Total Liabilities readings, the most recent being $2.5 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 25.2% to $2.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.5 million, a 25.2% decrease, with the full-year FY2025 number at $3.7 million, down 18.36% from a year prior.
  • Total Liabilities hit $2.5 million in Q1 2026 for Neuroone Medical Technologies, up from $2.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.5 million in Q3 2024 to a low of $952478.0 in Q2 2022.
  • Median Total Liabilities over the past 5 years was $1.9 million (2024), compared with a mean of $2.3 million.
  • Biggest five-year swings in Total Liabilities: crashed 42.58% in 2023 and later soared 153.46% in 2024.
  • Neuroone Medical Technologies' Total Liabilities stood at $1.5 million in 2022, then dropped by 5.66% to $1.4 million in 2023, then soared by 153.46% to $3.6 million in 2024, then plummeted by 38.87% to $2.2 million in 2025, then increased by 14.51% to $2.5 million in 2026.
  • The last three reported values for Total Liabilities were $2.5 million (Q1 2026), $2.2 million (Q4 2025), and $3.7 million (Q3 2025) per Business Quant data.